Impact of mesenchymal stem cells on the coagulation mechanism in patients with liver cirrhosis: A review and prospects

Abstract

Cirrhosis, characterized by extensive liver fibrosis and architectural distortion, is commonly associated with coagulation disorders that increase the risk of both bleeding and thrombosis. Mesenchymal stem cells (MSCs) have emerged as a promising therapeutic strategy for liver diseases, including cirrhosis, due to their regenerative and immunomodulatory properties. This review delves into the intricate relationship between MSCs and the coagulation system in cirrhotic patients, examining the impact on platelet dysfunction, coagulation factor synthesis, endothelial dysfunction, and fibrinolysis. The review highlights MSCs’ multilineage differentiation potential and their ability to secrete both procoagulant and anticoagulant factors, which are crucial in the context of liver disease. Clinical and preclinical findings on the effects of MSC therapy on coagulation are reviewed, along with safety and risk assessments. This review highlights the promising potential of MSCs in alleviating cirrhosis-associated coagulopathy, while identifying key challenges that must be addressed to advance clinical translation. Further research is therefore warranted to elucidate the underlying mechanisms and to optimize therapeutic strategies for clinical application.

Keywords

Mesenchymal stem cells (MSCs) / Liver cirrhosis / Coagulation mechanism / Blood coagulation / Liver function

References

[1] Zhou WC, Zhang QB, Qiao L. Pathogenesis of liver cirrhosis. World J Gastroenterol . 2014; 20:7312-7324. https://doi.org/10.3748/wjg.v20.i23.7312.

[2] Sun X, Yao L, Kang X, et al. Outcome of bariatric surgery in patients with unexpected liver cirrhosis: a multicenter study from China. Liver Res. 2024; 8:172-178. https://doi.org/10.1016/j.livres.2024.08.001.

[3] Abdelhamed W, El—Kassas M. Hepatitis B virus as a risk factor for hepatocellular carcinoma. Liver Res . 2024; 8:83-90. https://doi.org/10.1016/j.livres.2024.05.004.

[4] Ginès P, Krag A, Abraldes JG, Solà E, Fabrellas N, Kamath PS. Liver cirrhosis. Lancet. 2021; 398:1359-1376. https://doi.org/10.1016/S0140—6736(21)01374—X.

[5] Asrani SK, Devarbhavi H, Eaton J, Kamath PS. Burden of liver diseases in the world. J Hepatol. 2019; 70:151-171. https://doi.org/10.1016/j.jhep.2018.09.014.

[6] Roehlen N, Crouchet E, Baumert TF. Liver fibrosis: mechanistic concepts and therapeutic perspectives. Cells. 2020; 9:875. https://doi.org/10.3390/cells9040875.

[7] Pluta A, Gutkowski K, Hartleb M. Coagulopathy in liver diseases. Adv Med Sci . 2010; 55:16-21. https://doi.org/10.2478/v10039—010—0018—3.

[8] Wan C, He Q, McCaigue M, Marsh D, Li G. Nonadherent cell population of human marrow culture is a complementary source of mesenchymal stem cells (MSCs). J Orthop Res. 2006; 24:21-28. https://doi.org/10.1002/jor.20023.

[9] Du WJ, Chi Y, Yang ZX, et al. Heterogeneity of proangiogenic features in mesenchymal stem cells derived from bone marrow, adipose tissue, umbilical cord, and placenta.Stem Cell Res Ther . 2016; 7:163. https://doi.org/10.1186/s13287—016—0418—9.

[10] Christy BA, Herzig MC, Montgomery RK, et al. Procoagulant activity of human mesenchymal stem cells. J Trauma Acute Care Surg. 2017; 83:S164-S169. https://doi.org/10.1097/TA.0000000000001485.

[11] Amitrano L, Guardascione MA, Brancaccio V, Balzano A. Coagulation disorders in liver disease. Semin Liver Dis. 2002; 22:83-96. https://doi.org/10.1055/s—2002—23205.

[12] Lisman T, Caldwell SH, Intagliata NM. Haemostatic alterations and management of haemostasis in patients with cirrhosis. J Hepatol. 2022; 76:1291-1305. https://doi.org/10.1016/j.jhep.2021.11.004.

[13] Borensztajn K, von der Thüsen JH, Peppelenbosch MP, Spek CA. The coagulation factor xa/protease activated receptor—2 axis in the progression of liver fibrosis: a multifaceted paradigm. J Cell Mol Med. 2010; 14:143-153. https://doi.org/10.1111/j.1582—4934.2009.00980.x.

[14] Pant A, Kopec AK, Luyendyk JP. Role of the blood coagulation cascade in hepatic fibrosis. Am J Physiol Gastrointest Liver Physiol . 2018; 315:G171-G176. https://doi.org/10.1152/ajpgi.00402.2017.

[15] Borensztajn K, Stiekema J, Nijmeijer S, Reitsma PH, Peppelenbosch MP, Spek CA. Factor Xa stimulates proinflammatory and profibrotic responses in fibroblasts via protease—activated receptor—2 activation. Am J Pathol. 2008; 172:309-320. https://doi.org/10.2353/ajpath.2008.070347.

[16] Joseph C, Berghausen EM, Behringer A, et al. Coagulation—independent effects of thrombin and factor Xa: role of protease—activated receptors in pulmonary hypertension. Cardiovasc Res. 2022; 118:3225-3238. https://doi.org/10.1093/cvr/cvac004.

[17] de Ridder GG, Lundblad RL, Pizzo SV. Actions of thrombin in the interstitium. J Thrombos Haemost. 2016; 14:40-47. https://doi.org/10.1111/jth.13191.

[18] Monroe DM, Hoffman M, Roberts HR. Platelets and thrombin generation. Arterioscler Thromb Vasc Biol . 2002; 22:1381-1389. https://doi.org/10.1161/01.atv.0000031340.68494.34.

[19] Negrier C, Shima M, Hoffman M. The central role of thrombin in bleeding disorders. Blood Rev. 2019; 38:100582. https://doi.org/10.1016/j.blre.2019.05.006.

[20] Maharshak N, Halfon P, Deutsch V, et al. Increased fibrosis progression rates in hepatitis C patients carrying the prothrombin G20210A mutation. World J Gastroenterol. 2011; 17:5007-5013. https://doi.org/10.3748/wjg.v17.i45.5007.

[21] Wright M, Goldin R, Hellier S, et al. Factor v leiden polymorphism and the rate of fibrosis development in chronic hepatitis C virus infection. Gut. 2003; 52:1206-1210. https://doi.org/10.1136/gut.52.8.1206.

[22] Violi F, Ferro D, Basili S. Coagulopathy of chronic liver disease. N Engl J Med. 2011; 365:147-156. https://doi.org/10.1056/NEJMc1109231. author reply 1453—4.

[23] Lisman T, Leebeek FWG, de Groot PG. Haemostatic abnormalities in patients with liver disease. J Hepatol. 2002; 37:280-287. https://doi.org/10.1016/s0168—8278(02)00199—x.

[24] Wada H, Usui M, Sakuragawa N. Hemostatic abnormalities and liver diseases. Semin Thromb Hemost . 2008; 34:772-778. https://doi.org/10.1055/s—0029—1145259.

[25] Bianchini M, Pietri LD, Villa E. Coagulopathy in liver diseases: complication or therapy? Digestive Dis. 2014; 32:609-614. https://doi.org/10.1159/000360514.

[26] Rezaie AR, Giri H. Anticoagulant and signaling functions of antithrombin. J Thrombos Haemost . 2020; 18:3142-3153. https://doi.org/10.1111/jth.15052.

[27] Maruyama K, Kokame K. Carrier frequencies of antithrombin, protein C, and protein s deficiency variants estimated using a public database and expression experiments. Res Pract Thromb Haemost. 2021; 5:179-186. https://doi.org/10.1002/rth2.12456.

[28] Luyendyk JP, Schoenecker JG, Flick MJ. The multifaceted role of fibrinogen in tissue injury and inflammation. Blood. 2019; 133:511-520. https://doi.org/10.1182/blood—2018—07—818211.

[29] Tennent GA, Brennan SO, Stangou AJ, O’Grady J, Hawkins PN, Pepys MB. Human plasma fibrinogen is synthesized in the liver. Blood. 2007; 109:1971-1974. https://doi.org/10.1182/blood—2006—08—040956.

[30] Gligorijević N, Minić S, Križaková M, Katrlík J, Nedić O. Structural changes of fibrinogen as a consequence of cirrhosis. Thrombosis Res . 2018; 166:43-49. https://doi.org/10.1016/j.thromres.2018.04.005.

[31] Martinez J, MacDonald KA, Palascak JE. The role of sialic acid in the dysfibrinogenemia associated with liver disease: distribution of sialic acid on the constituent chains. Blood. 1983; 61:1196-1202.

[32] Koupenova M, Clancy L, Corkrey HA, Freedman E. Circulating platelets as mediators of immunity, inflammation, and thrombosis. Circ Res. 2018; 122:337-351. https://doi.org/10.1161/CIRCRESAHA.117.310795.

[33] Marie PK, Fowlkes NW, Afshar—Kharghan V, et al. The provocative roles of platelets in liver disease and cancer. Front Oncol . 2021; 11:643815. https://doi.org/10.3389/fonc.2021.643815.

[34] Afdhal N, McHutchison J, Brown R, et al. Thrombocytopenia associated with chronic liver disease. J Hepatol. 2008; 48:1000-1007. https://doi.org/10.1016/j.jhep.2008.03.009.

[35] Roberts LN, Lisman T, Stanworth S, et al. Periprocedural management of abnormal coagulation parameters and thrombocytopenia in patients with cirrhosis: guidance from the SSC of the ISTH. J Thrombosis Haemostasis. 2022; 20:39-47. https://doi.org/10.1111/jth.15562.

[36] Peck—Radosavljevic M. Thrombocytopenia in chronic liver disease. Liver Int. 2017; 37:778-793. https://doi.org/10.1111/liv.13317.

[37] Nomura S, Ogami K, Kawamura K, et al. Cellular localization of thrombopoietin mrna in the liver by in situ hybridization. Exp Hematol. 1997; 25:565-572.

[38] Qian S, Fu F, Li W, Chen Q, de Sauvage FJ. Primary role of the liver in thrombopoietin production shown by tissue—specific knockout. Blood. 1998; 92:2189-2191.

[39] Peck—Radosavljevic M, Simon K, Iacobellis A, et al. Lusutrombopag for the treatment of thrombocytopenia in patients with chronic liver disease undergoing invasive procedures (L—PLUS 2). Hepatology. 2019; 70:1336-1348. https://doi.org/10.1002/hep.30561.

[40] Liu P, Hum J, Jou J, Scanlan RM, Shatzel J. Transfusion strategies in patients with cirrhosis. Eur J Haematology . 2020; 104:15-25. https://doi.org/10.1111/ejh.13342.

[41] Kim OV, Nevzorova TA, Mordakhanova ER, et al. Fatal dysfunction and disintegration of thrombin—stimulated platelets. Haematologica . 2019; 104:1866-1878. https://doi.org/10.3324/haematol.2018.202309.

[42] Shimizu M, Natori T, Tsuda K, et al. Thrombin—induced platelet aggregation —effect of dabigatran using automated platelet aggregometry. Platelets. 2020; 31:360-364. https://doi.org/10.1080/09537104.2019.1624707.

[43] Kohlmorgen C, Gerfer S, Feldmann K, et al. Dapagliflozin reduces thrombin generation and platelet activation: implications for cardiovascular risk reduction in type 2 diabetes mellitus. Diabetologia . 2021; 64:1834-1849. https://doi.org/10.1007/s00125—021—05498—0.

[44] Holt AP, Salmon M, Buckley CD, Adams DH. Immune interactions in hepatic fibrosis. Clin Liver Dis . 2008; 12:861-882. https://doi.org/10.1016/j.cld.2008.07.002.x.

[45] Heijnen H, van der Sluijs P. Platelet secretory behaviour: as diverse as the granules … or not? J Thrombosis and Haemostasis. 2015; 13:2141-2151. https://doi.org/10.1111/jth.13147.

[46] Kotlyarov S. Immune function of endothelial cells: evolutionary aspects, molecular biology and role in atherogenesis. Int J Mol Sci . 2022; 23:9770. https://doi.org/10.3390/ijms23179770.

[47] Pober JS, Sessa WC. Evolving functions of endothelial cells in inflammation. Nat Rev Immunol . 2007; 7:803-815. https://doi.org/10.1038/nri2171.

[48] Wang X, Shen Y, Shang M, Liu X, Munn LL. Endothelial mechanobiology in atherosclerosis. Cardiovasc Res . 2023; 119:1656-1675. https://doi.org/10.1093/cvr/cvad076.

[49] Maxime D, Alexandra D, Peter S, Isabelle AL. Critical role of LSEC in post—hepatectomy liver regeneration and failure. Int J Mol Sci. 2021; 22:8053. https://doi.org/10.3390/ijms22158053.

[50] Poisson J, Lemoinne S, Boulanger C, et al. Liver sinusoidal endothelial cells: physiology and role in liver diseases. J Hepatol. 2017; 66:212-227. https://doi.org/10.1016/j.jhep.2016.07.009.

[51] Mura VL, Reverter JC, Flores—Arroyo A, et al. Von willebrand factor levels predict clinical outcome in patients with cirrhosis and portal hypertension. Gut. 2011; 60:1133-1138. https://doi.org/10.1136/gut.2010.235689.

[52] Ferlitsch M, Reiberger T, Hoke M, et al. Von willebrand factor as new noninvasive predictor of portal hypertension, decompensation and mortality in patients with liver cirrhosis. Hepatology. 2012; 56:1439-1447. https://doi.org/10.1002/hep.25806.

[53] Maieron A, Salzl P, Peck—Radosavljevic M, et al. Von willebrand factor as a new marker for non—invasive assessment of liver fibrosis and cirrhosis in patients with chronic hepatitis C. Aliment Pharmacol Ther. 2014; 39:331-338. https://doi.org/10.1111/apt.12564.

[54] Kalambokis GN, Oikonomou A, Christou L, et al. Von willebrand factor and procoagulant imbalance predict outcome in patients with cirrhosis and thrombocytopenia. J Hepatol. 2016; 65:921-928. https://doi.org/10.1016/j.jhep.2016.06.002.

[55] Iwakiri Y, Groszmann RJ. Vascular endothelial dysfunction in cirrhosis. J Hepatol. 2007; 46:927-934. https://doi.org/10.1016/j.jhep.2007.02.006.

[56] Jiang Y, Xiang C, Zhong F, et al. Histone H3K27 methyltransferase EZH2 and demethylase JMJD3 regulate hepatic stellate cells activation and liver fibrosis. Theranostics. 2021; 11:361-378. https://doi.org/10.7150/thno.46360.

[57] Stravitz RT. Algorithms for managing coagulation disorders in liver disease. Hepatol Int. 2018; 12:390-401. https://doi.org/10.1007/s12072—018—9886—6.

[58] Wang YH, Wu DB, Chen B, Chen EQ, Tang H. Progress in mesenchymal stem cell—based therapy for acute liver failure. Stem Cell Res Ther. 2018; 9:227. https://doi.org/10.1186/s13287—018—0972—4.

[59] Shi M, Li YY, Xu RN, et al. Mesenchymal stem cell therapy in decompensated liver cirrhosis: a long—term follow—up analysis of the randomized controlled clinical trial. Hepatol Int. 2021; 15:1431-1441. https://doi.org/10.1007/s12072—021—10199—2.

[60] Li Z, Hu X, Zhong JF. Mesenchymal stem cells: characteristics, function, and application.Stem Cell Int . 2019; 2019:8106818. https://doi.org/10.1155/2019/8106818.

[61] Yi X, Chen F, Liu F, et al. Comparative separation methods and biological characteristics of human placental and umbilical cord mesenchymal stem cells in serum—free culture conditions. Stem Cell Res Ther . 2020; 11:183. https://doi.org/10.1186/s13287—020—01690—y.

[62] Zen NTK, Zeming KK, Teo KL, et al. Scalable mesenchymal stem cell enrichment from bone marrow aspirate using deterministic lateral displacement (DLD) microfluidic sorting. Lab Chip. 2023; 23:4313-4323. https://doi.org/10.1039/d3lc00379e.

[63] Li J, Wu Z, Zhao L, et al. The heterogeneity of mesenchymal stem cells: an important issue to be addressed in cell therapy. Stem Cell Res Ther . 2023; 14:381. https://doi.org/10.1186/s13287—023—03587—y.

[64] Drela K, Stanaszek L, Snioch K, et al. Bone marrow—derived from the human femoral shaft as a new source of mesenchymal stem/stromal cells: an alternative cell material for banking and clinical transplantation. Stem Cell Res Ther. 2020; 11:262. https://doi.org/10.1186/s13287—020—01697—5.

[65] Dehnavi S, Sadeghi M, Afshari JT, Mohammadi M. Interactions of mesenchymal stromal/stem cells and immune cells following MSC—based therapeutic approaches in rheumatoid arthritis. Cell Immunol. 2023; 393—394:104771. https://doi.org/10.1016/j.cellimm.2023.104771.

[66] Shang L, Shao J, Ge S. Immunomodulatory functions of oral mesenchymal stem cells: novel force for tissue regeneration and disease therapy. J Leukoc Biol. 2021; 110:539-552. https://doi.org/10.1002/JLB.3MR0321—766R.

[67] Divisato G, Piscitelli S, Elia M, Cascone E, Parisi S. Micrornas and stem—like properties: the complex regulation underlying stemness maintenance and cancer development. Biomolecules. 2021; 11:1074. https://doi.org/10.3390/biom11081074.

[68] Naji A, Eitoku M, Favier B, Deschaseaux F, Rouas—Freiss N, Suganuma N. Biological functions of mesenchymal stem cells and clinical implications. Cell Mol Life Sci. 2019; 76:3323-3348. https://doi.org/10.1007/s00018—019—03125—1.

[69] Wang B, Wu SM, Wang T, et al. Pre—treatment with bone marrow—derived mesenchymal stem cells inhibits systemic intravascular coagulation and attenuates organ dysfunction in lipopolysaccharide—induced disseminated intravascular coagulation rat model. Chin Med J. 2012; 125:1753-1759. doi: 10.3760/cma.j.issn.0366—6999.2012.10.013.

[70] Tan L, Huang Y, Pan X, et al. Administration of bone marrow stromal cells in sepsis attenuates sepsis—related coagulopathy. Ann Med . 2016; 48:235-245. https://doi.org/10.3109/07853890.2016.1157725.

[71] Xiu G, Xiong W, Yin Y, et al. [Role of HMGB1—RAGE/TLRs—NF—κB signaling pathway on bone mesenchymal stem cells transplantation therapy for lipopolysaccaride—induced coagulation disorder rats]. Zhonghua Wei Zhong Bing Ji Jiu Yi Xue. 2018; 30:830-835. https://doi.org/10.3760/cma.j.issn.2095—4352.2018.09.003.

[72] Wu CX, Wang D, Cai Y, Luo AR, Sun H. Effect of autologous bone marrow stem cell therapy in patients with liver cirrhosis: a meta—analysis. J Clin Transl Hepatol. 2019; 7:238-248. https://doi.org/10.14218/JCTH.2019.00008.

[73] Lai RC, Lim SK. Membrane lipids define small extracellular vesicle subtypes secreted by mesenchymal stromal cells.J Lipid Res . 2019; 60:318-322. https://doi.org/10.1194/jlr.R087411.

[74] Spronk HMH, ten Cate H, van der Meijden PEJ. Differential roles of tissue factor and phosphatidylserine in activation of coagulation. Thromb Res . 2014; 133:S54-S56. https://doi.org/10.1016/j.thromres.2014.03.022.

[75] Griffith L, Slupsky J, Seehafer J, Boshkov L, Shaw AR. Platelet activation by immobilized monoclonal antibody: evidence for a CD9 proximal signal. Blood. 1991; 78:1753-1759.

[76] Israels SJ, McMillan—Ward EM. Palmitoylation supports the association of tetraspanin CD63 with CD9 and integrin alphaiibbeta3 in activated platelets. Thrombosis Res. 2010; 125:152-158. https://doi.org/10.1016/j.thromres.2009.07.005.

[77] Semeraro F, Ammollo CT, Morrissey JH, et al. Extracellular histones promote thrombin generation through platelet—dependent mechanisms: involvement of platelet TLR2 and TLR4. Blood. 2011; 118:1952-1961. https://doi.org/10.1182/blood—2011—03—343061.

[78] Deguchi H, Sinha RK, Marchese P, et al. Prothrombotic skeletal muscle myosin directly enhances prothrombin activation by binding factors Xa and Va. Blood. 2016; 128:1870-1878. https://doi.org/10.1182/blood—2016—03—707679.

[79] Silachev DN, Goryunov KV, Shpilyuk MA, et al. Effect of mscs and MSC—derived extracellular vesicles on human blood coagulation. Cells. 2019; 8:258. https://doi.org/10.3390/cells8030258.

[80] Fiedler T, Rabe M, Mundkowski RG, Oehmcke—Hecht S, Peters K. Adipose—derived mesenchymal stem cells release microvesicles with procoagulant activity. Int J Biochem Cell Biol. 2018; 100:49-53. https://doi.org/10.1016/j.biocel.2018.05.008.

[81] Perlee D, van Vught LA, Scicluna BP, et al. Intravenous infusion of human adipose mesenchymal stem cells modifies the host response to lipopolysaccharide in humans: a randomized, single—blind, parallel group, placebo controlled trial. Stem Cell . 2018; 36:1778-1788. https://doi.org/10.1002/stem.2891.

[82] Liu TX, Wang YX, Ding YB. Advances in placenta—derived stem cells. Chin J Prenat Diagn (Electr Vers). 2018; 10:1-5.

[83] Moll G, Ignatowicz L, Catar R, et al. Different procoagulant activity of therapeutic mesenchymal stromal cells derived from bone marrow and placental decidua. Stem Cell Dev . 2015; 24:2269-2279. https://doi.org/10.1089/scd.2015.0120.

[84] Choi BY, Kim OJ, Min SH, Jeong JH, Suh SW, Chung TN. Human placenta—derived mesenchymal stem cells reduce mortality and hematoma size in a rat intracerebral hemorrhage model in an acute phase. Stem Cell Int. 2018; 2018:1658195. https://doi.org/10.1155/2018/1658195.

[85] Netsch P, Elvers—Hornung S, Uhlig S, et al. Human mesenchymal stromal cells inhibit platelet activation and aggregation involving CD73—converted adenosine. Stem Cell Res Ther. 2018; 9:184. https://doi.org/10.1186/s13287—018—0936—8.

[86] Shi L, Zhang Z, Mei S, et al. Dose—escalation studies of mesenchymal stromal cell therapy for decompensated liver cirrhosis: phase ia/ib results and immune modulation insights. Signal Transduct Target Ther. 2025; 10:238. https://doi.org/10.1038/s41392—025—02318—4.

[87] Sun T, Li H, Bai Y, et al. Ultrasound—targeted microbubble destruction optimized HGF—overexpressing bone marrow stem cells to repair fibrotic liver in rats. Stem Cell Res Ther. 2020; 11:145. https://doi.org/10.1186/s13287—020—01655—1.

[88] Baz HE, Demerdash Z, Kamel M, et al. Transplant of hepatocytes, undifferentiated mesenchymal stem cells, and in vitro hepatocyte—differentiated mesenchymal stem cells in a chronic liver failure experimental model: a comparative study. Exp Clin Transplantion. 2018; 16:81-89. https://doi.org/10.6002/ect.2016.0226.

[89] Ren H, Zhao Q, Cheng T, et al. No contribution of umbilical cord mesenchymal stromal cells to capillarization and venularization of hepatic sinusoids accompanied by hepatic differentiation in carbon tetrachloride—induced mouse liver fibrosis. Cytotherapy. 2010; 12:371-383. https://doi.org/10.3109/14653241003596661.

[90] Xiang E, Han B, Zhang Q, et al. Human umbilical cord—derived mesenchymal stem cells prevent the progression of early diabetic nephropathy through inhibiting inflammation and fibrosis. Stem Cell Res Ther. 2020; 11:336. https://doi.org/10.1186/s13287—020—01852—y.

[91] Green M, Saha P. Case study: acute iliofemoral DVT in a young female with factor V leiden. J Vasc Nurs. 2021; 39:104-107. https://doi.org/10.1016/j.jvn.2021.07.006.

[92] Zekri ARN, Salama H, Medhat E, et al. The impact of repeated autologous infusion of haematopoietic stem cells in patients with liver insufficiency. Stem Cell Res Ther . 2015; 6:118. https://doi.org/10.1186/s13287—015—0106—1.

[93] Wu F, She Z, Li C, et al. Therapeutic potential of mscs and MSC—derived extracellular vesicles in immune thrombocytopenia.Stem Cell Res Ther . 2023; 14:79. https://doi.org/10.1186/s13287—023—03323—6.

[94] Liu Z, Ren J, Qiu C, Wang Y, Zhang T. Application of mesenchymal stem cells in liver fibrosis and regeneration. Liver Res. 2024; 8:246-258. https://doi.org/10.1016/j.livres.2024.11.004.

[95] Yi T, Song SU. Immunomodulatory properties of mesenchymal stem cells and their therapeutic applications. Arch Pharm Res. 2012; 35:213-221. https://doi.org/10.1007/s12272—012—0202—z.

[96] Huang B, Cheng X, Wang H, et al. Mesenchymal stem cells and their secreted molecules predominantly ameliorate fulminant hepatic failure and chronic liver fibrosis in mice respectively. J Transl Med . 2016; 14:45. https://doi.org/10.1186/s12967—016—0792—1.

[97] Lange C, Bassler P, Lioznov MV, et al. Liver—specific gene expression in mesenchymal stem cells is induced by liver cells. World J Gastroenterol. 2005; 11:4497-4504. https://doi.org/10.3748/wjg.v11.i29.4497.

[98] Kang SH, Kim MY, Eom YW, Baik SK. Mesenchymal stem cells for the treatment of liver disease: present and perspectives. Gut Liver. 2020; 14:306-315. https://doi.org/10.5009/gnl18412.

[99] Schwartz RE, Reyes M, Koodie L, et al. Multipotent adult progenitor cells from bone marrow differentiate into functional hepatocyte—like cells. J Clin Invest. 2002; 109:1291-1302. https://doi.org/10.1172/JCI15182.

[100] Sun H, Shi C, Ye Z, et al. The role of mesenchymal stem cells in liver injury. Cell Biol Int . 2022; 46:501-511. https://doi.org/10.1002/cbin.11725.

[101] Lin F, Chen W, Zhou J, et al. Mesenchymal stem cells protect against ferroptosis via exosome—mediated stabilization of SLC7A11 in acute liver injury. Cell Death Dis. 2022; 13:271. https://doi.org/10.1038/s41419—022—04708—w.

[102] Tian S, Zhou X, Zhang M, et al. Mesenchymal stem cell—derived exosomes protect against liver fibrosis via delivering mir—148a to target KLF6/STAT3 pathway in macrophages. Stem Cell Res Ther. 2022; 13:330. https://doi.org/10.1186/s13287—022—03010—y.

[103] Wang H, Yao W, Wang Y, et al. Meta—analysis on last ten years of clinical injection of bone marrow—derived and umbilical cord MSC to reverse cirrhosis or rescue patients with acute—on—chronic liver failure. Stem Cell Res Ther. 2023; 14:267. https://doi.org/10.1186/s13287—023—03494—2.

[104] Jiang W, Xu J. Immune modulation by mesenchymal stem cells. Cell Prolif . 2020; 53:e12712. https://doi.org/10.1111/cpr.12712.

[105] Lu T, Zhang J, Cai J, et al. Extracellular vesicles derived from mesenchymal stromal cells as nanotherapeutics for liver ischaemia—reperfusion injury by transferring mitochondria to modulate the formation of neutrophil extracellular traps. Biomaterials. 2022; 284:121486. https://doi.org/10.1016/j.biomaterials.2022.121486.

[106] Jun JH, Jung J, Kim JY, Hwang SG, Bae SH, Kim GJ. Upregulation of C—Reactive protein by placenta—derived mesenchymal stem cells promotes angiogenesis in a rat model with cirrhotic liver. Int J Stem Cells. 2020; 13:404-413. https://doi.org/10.15283/ijsc20052.

[107] Lin Y, Yan M, Bai Z, et al. Huc—MSC—derived exosomes modified with the targeting peptide of ahscs for liver fibrosis therapy. J Nanobiotechnology. 2022; 20:432. https://doi.org/10.1186/s12951—022—01636—x.

[108] Salama H, Zekri ARN, Medhat E, et al. Peripheral vein infusion of autologous mesenchymal stem cells in egyptian HCV—positive patients with end—stage liver disease. Stem Cell Res Ther. 2014; 5:70. https://doi.org/10.1186/scrt459.

[109] Lyra AC, Soares MBP, da Silva LFM, et al. Infusion of autologous bone marrow mononuclear cells through hepatic artery results in a short—term improvement of liver function in patients with chronic liver disease: a pilot randomized controlled study. Eur J Gastroenterol Hepatol. 2010; 22:33-42. https://doi.org/10.1097/MEG.0b013e32832eb69a.

[110] Aithal AP, Bairy LK, Seetharam RN, Kumar N. Haemostatic potential of human bone marrow—derived mesenchymal stromal cells in wistar rats with carbon tetrachloride induced liver cirrhosis. Stem Cell Investig. 2018; 5:21. https://doi.org/10.21037/sci.2018.07.04.

[111] Suk KT, Yoon JH, Kim MY, et al. Transplantation with autologous bone marrow—derived mesenchymal stem cells for alcoholic cirrhosis: phase 2 trial. Hepatology. 2016; 64:2185-2197. https://doi.org/10.1002/hep.28693.

[112] Zhang Z, Lin H, Shi M, et al. Human umbilical cord mesenchymal stem cells improve liver function and ascites in decompensated liver cirrhosis patients. J Gastroenterol Hepatol. 2012; 27:112-120. https://doi.org/10.1111/j.1440—1746.2011.07024.x.

[113] Fang X, Liu L, Dong J, et al. A study about immunomodulatory effect and efficacy and prognosis of human umbilical cord mesenchymal stem cells in patients with chronic hepatitis B—induced decompensated liver cirrhosis. J Gastroenterol Hepatol. 2018; 33:774-780. https://doi.org/10.1111/jgh.14081.

[114] Mu K, Zhang J, Gu Y, et al. Cord—derived mesenchymal stem cells therapy for liver cirrhosis in children with refractory Henoch—Schonlein purpura: a case report. Medicine . 2018; 97:e13287. https://doi.org/10.1097/MD.0000000000013287.

[115] Jung JW, Kwon M, Choi JC, et al. Familial occurrence of pulmonary embolism after intravenous, adipose tissue—derived stem cell therapy. Yonsei Med J. 2013; 54:1293-1296. https://doi.org/10.3349/ymj.2013.54.5.1293.

[116] Tatsumi K, Ohashi K, Matsubara Y, et al. Tissue factor triggers procoagulation in transplanted mesenchymal stem cells leading to thromboembolism. Biochem Biophys Res Commun . 2013; 431:203-209. https://doi.org/10.1016/j.bbrc.2012.12.134.

[117] Coppin LCF, Smets F, Ambroise J, Sokal EEM, Stéphenne X. Infusion—related thrombogenesis by liver—derived mesenchymal stem cells controlled by anticoagulant drugs in 11 patients with liver—based metabolic disorders. Stem Cell Res Ther. 2020; 11:51. https://doi.org/10.1186/s13287—020—1572—7.

[118] Moll G, Ankrum JA, Olson SD, Nolta JA. Improved MSC minimal criteria to maximize patient safety: a call to embrace tissue factor and hemocompatibility assessment of MSC products. Stem Cells Transl Med. 2022; 11:2-13. https://doi.org/10.1093/stcltm/szab005.

[119] Witkowski M, Landmesser U, Rauch U. Tissue factor as a link between inflammation and coagulation. Trends Cardiovasc Med . 2016; 26:297-303. https://doi.org/10.1016/j.tcm.2015.12.001.

[120] Furie B, Furie BC. Mechanisms of thrombus formation. N Engl J Med. 2008; 359:938-949. https://doi.org/10.1056/NEJMra0801082.

[121] Coppin L, Sokal E, Stéphenne X. Thrombogenic risk induced by intravascular mesenchymal stem cell therapy: current status and future perspectives. Cells. 2019; 8:1160. https://doi.org/10.3390/cells8101160.

[122] Moll G, Rasmusson—Duprez I, von Bahr L, et al. Are therapeutic human mesenchymal stromal cells compatible with human blood? Stem Cell . 2012; 30:1565-1574. https://doi.org/10.1002/stem.1111.

[123] Eirin A, Zhu XY, Puranik AS, et al. Comparative proteomic analysis of extracellular vesicles isolated from porcine adipose tissue—derived mesenchymal stem/stromal cells. Sci Rep. 2016; 6:36120. https://doi.org/10.1038/srep36120.

[124] Levy JH, Connors JM. Heparin resistance — clinical perspectives and management strategies. N Engl J Med. 2021; 385:826-832. https://doi.org/10.1056/NEJMra2104091.